Immunic (IMUX) Stock Price

Immunic Price

Frankfurt·CLOSED
14.66USD-0.11 (-0.75 %)
Market closed

Analysts set a median price target of 4.08 USD, implying 72.2% below the current price. Of 15 analysts, 14 rate the stock a buy — an overall Buy consensus. Over the past year Immunic shares have gained 1,659.7%. The stock trades about 2,773% above its 52-week low.

Immunic stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Immunic over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Immunic stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Immunic's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Immunic Stock Price History
DateImmunic Price
7/13/202614.66 USD
7/10/202614.77 USD
7/9/202614.78 USD
7/8/202614.59 USD
7/7/202615.36 USD
7/6/202614.74 USD
7/2/202614.80 USD
7/1/202614.81 USD
6/30/202615.37 USD
6/29/202615.41 USD
6/26/202615.30 USD
6/25/202615.07 USD
6/24/202614.71 USD
6/23/202615.07 USD
6/22/202614.68 USD
6/18/202614.20 USD
6/17/202614.20 USD
6/16/202613.71 USD
6/15/202614.01 USD
6/12/202613.86 USD
5/13/202612.95 USD
5/4/202610.62 USD
4/22/20260.90 USD
4/21/20260.90 USD
4/20/20260.96 USD
4/16/20261.00 USD
4/15/20261.11 USD
4/14/20261.18 USD
4/13/20261.22 USD
4/9/20261.29 USD
4/8/20261.19 USD
4/7/20261.19 USD
4/6/20261.17 USD
4/2/20261.16 USD
4/1/20261.15 USD
3/31/20261.11 USD
3/30/20261.03 USD
3/27/20261.09 USD
3/26/20261.26 USD
3/25/20261.32 USD
3/24/20261.25 USD
3/23/20261.17 USD
3/20/20261.10 USD
3/19/20261.16 USD
3/18/20261.15 USD
3/17/20261.20 USD
3/16/20261.16 USD
3/13/20261.17 USD
3/12/20261.37 USD
3/11/20261.45 USD
3/10/20261.29 USD
3/9/20261.25 USD
3/6/20261.23 USD
3/5/20261.11 USD
3/4/20261.17 USD
3/3/20261.07 USD
3/2/20261.06 USD
2/27/20261.02 USD
2/26/20260.95 USD
2/25/20260.91 USD
2/24/20260.90 USD
2/23/20260.87 USD
2/20/20260.94 USD
2/19/20260.97 USD
2/18/20260.88 USD
2/17/20260.92 USD
2/13/20260.91 USD
2/12/20260.87 USD
2/11/20260.74 USD
2/10/20260.79 USD
2/9/20260.71 USD
2/6/20260.62 USD
2/5/20260.59 USD
2/4/20260.62 USD
2/3/20260.66 USD
2/2/20260.65 USD
1/30/20260.63 USD
1/29/20260.61 USD
1/28/20260.61 USD
1/27/20260.62 USD
1/26/20260.69 USD
1/23/20260.69 USD
1/22/20260.69 USD
1/21/20260.66 USD
1/20/20260.64 USD
1/16/20260.62 USD
1/15/20260.64 USD
1/14/20260.65 USD
1/13/20260.68 USD
1/12/20260.66 USD
1/9/20260.66 USD
1/8/20260.66 USD
1/7/20260.69 USD
1/6/20260.62 USD
1/5/20260.64 USD
1/2/20260.58 USD
12/31/20250.53 USD
12/30/20250.51 USD
12/29/20250.52 USD
12/26/20250.56 USD
12/24/20250.58 USD
12/23/20250.57 USD
12/22/20250.60 USD
12/19/20250.57 USD
12/18/20250.57 USD
12/17/20250.58 USD
12/16/20250.60 USD
12/15/20250.61 USD
12/12/20250.62 USD
12/11/20250.66 USD
12/10/20250.68 USD
12/9/20250.67 USD
12/8/20250.67 USD
12/5/20250.66 USD
12/4/20250.69 USD
12/3/20250.65 USD
12/2/20250.65 USD
12/1/20250.68 USD
11/28/20250.71 USD
11/26/20250.70 USD
11/25/20250.71 USD
11/24/20250.69 USD
11/21/20250.69 USD
11/20/20250.69 USD
11/19/20250.71 USD
11/18/20250.76 USD
11/17/20250.73 USD
11/14/20250.78 USD
11/13/20250.71 USD
11/12/20250.76 USD
11/11/20250.78 USD
11/10/20250.76 USD
11/7/20250.72 USD
11/6/20250.70 USD
11/5/20250.72 USD
11/4/20250.69 USD
11/3/20250.75 USD
10/31/20250.78 USD
10/30/20250.78 USD
10/29/20250.80 USD
10/28/20250.84 USD
10/27/20250.84 USD
10/23/20250.78 USD
10/22/20250.79 USD
10/21/20250.82 USD
10/20/20250.84 USD
10/16/20250.82 USD
10/15/20250.84 USD
10/14/20250.85 USD
10/13/20250.89 USD
10/9/20250.92 USD
10/8/20250.90 USD
10/7/20250.88 USD
10/6/20250.94 USD
10/2/20250.96 USD
10/1/20250.96 USD
9/30/20250.88 USD
9/29/20250.93 USD
9/25/20250.90 USD
9/24/20250.88 USD
9/23/20250.89 USD
9/22/20250.91 USD
9/18/20250.84 USD
9/17/20250.83 USD
9/16/20250.82 USD
9/15/20250.77 USD
9/11/20250.85 USD
9/10/20250.87 USD
9/9/20250.86 USD
9/8/20250.83 USD
9/4/20250.77 USD
9/3/20250.80 USD
9/2/20250.80 USD
8/28/20250.87 USD
8/27/20250.85 USD
8/26/20250.88 USD
8/25/20250.88 USD
8/21/20250.94 USD
8/20/20250.92 USD
8/19/20250.91 USD
8/18/20250.98 USD
8/14/20250.92 USD
8/13/20250.83 USD
8/12/20250.85 USD
8/11/20250.85 USD
8/7/20250.90 USD
8/6/20250.98 USD
8/5/20250.98 USD
8/4/20250.98 USD
7/31/20250.94 USD
7/30/20250.96 USD
7/29/20250.98 USD
7/28/20251.08 USD
7/24/20251.07 USD
7/23/20251.00 USD
7/22/20250.94 USD
7/21/20250.93 USD
7/17/20250.93 USD
7/16/20250.90 USD
7/15/20250.83 USD
Access this data via the Eulerpool API
Get Free API Key

Immunic Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
0.00 USD
-99.22 M USD
-93.61 M USD
Jan 1, 2024
0.00 USD
-98.05 M USD
-100.51 M USD
Jan 1, 2025
0.00 USD
-103.23 M USD
-97.17 M USD
Jan 1, 2026 (e)
0.00 USD
-114.25 M USD
-527.22 M USD
Jan 1, 2027 (e)
11.11 M USD
-119.33 M USD
-426.55 M USD
Jan 1, 2028 (e)
219.83 M USD
-14.52 M USD
-15.46 M USD
Jan 1, 2029 (e)
584.00 M USD
96.23 M USD
22.82 M USD
Jan 1, 2030 (e)
1.04 B USD
421.01 M USD
0.00 USD

Immunic Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 15, 2026, 8:00 PM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEk USD
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
20162017201820192020202120222023202420252026e2027e2028e2029e2030e2031e
–––––––––––0.010.220.581.041.58
––––––––––––1,890.91166.6777.7452.22
–––––––––––-9.09-0.46-0.17-0.10-0.06
-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00
-40.00-52.00-41.00-34.00-44.00-92.00-120.00-93.00-100.00-97.00-527.00-426.00-15.0022.00–179.00
-23.0830.00-21.15-17.0729.41109.0930.43-22.507.53-3.00443.30-19.17-96.48-246.67––
0.080.110.111.072.122.533.184.469.0215.5715.5715.5715.5715.5715.5715.57
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Immunic generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Immunic retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Immunic's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Immunic has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Immunic's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Immunic stock margins

The Immunic margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Immunic. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Immunic.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
96.57 %
- %
- %
Jan 1, 2022
96.57 %
- %
- %
Jan 1, 2023
96.57 %
- %
- %
Jan 1, 2024
96.57 %
- %
- %
Jan 1, 2025
96.57 %
- %
- %
Jan 1, 2026 (e)
96.57 %
- %
- %
Jan 1, 2027 (e)
96.57 %
-1,073.94 %
-3,838.94 %
Jan 1, 2028 (e)
96.57 %
-6.61 %
-7.03 %

Immunic Stock Revenue, EBIT, Earnings per Share

The Immunic earnings per share therefore indicates how much revenue Immunic has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.00 USD
-36.20 USD
-36.65 USD
Jan 1, 2022
0.00 USD
-37.55 USD
-37.84 USD
Jan 1, 2023
0.00 USD
-22.23 USD
-20.97 USD
Jan 1, 2024
0.00 USD
-10.88 USD
-11.15 USD
Jan 1, 2025
0.00 USD
-6.63 USD
-6.24 USD
Jan 1, 2026 (e)
0.00 USD
-7.34 USD
-4.38 USD
Jan 1, 2027 (e)
0.09 USD
-7.66 USD
-3.55 USD
Jan 1, 2028 (e)
1.83 USD
-0.93 USD
-0.13 USD

Immunic business model & stock analysis

Immunic Inc is a biotechnology company specialized in the development of therapeutics for chronic inflammatory and autoimmune diseases. The company was founded in 2016 as a spin-off of the Max Planck Institute for Infection Biology in Berlin and is based in New York City. Immunic Inc aims to develop innovative drugs that improve the quality of life for patients with chronic inflammatory and autoimmune diseases and positively influence the course of their conditions. The business activities of Immunic Inc include the identification of new active substances, drug development, clinical studies, and drug approval by regulatory authorities. To accelerate drug development, the company collaborates with academic, regulatory, and pharmaceutical partners. Immunic Inc offers products in three different areas: autoimmune diseases, inflammatory diseases, and infectious diseases. Each area has various products and pipelines currently in development. In the field of autoimmune diseases, the main product of Immunic Inc is the substance IMU-838. This drug is a highly effective inhibitor of the DHODH enzyme family, which plays an essential role in mitochondrial DNA synthesis. IMU-838 is a very selective DHODH inhibitor with disease-specific effects against various autoimmune diseases. IMU-838 is one of the most promising candidates of Immunic Inc and is currently in phase II studies for the treatment of multiple sclerosis (MS), ulcerative colitis, and chronic inflammatory bowel diseases (CED). In the field of inflammatory diseases, Immunic Inc is developing a drug based on IMM-124E. This medication is an orally administered therapeutic agent that inhibits inflammatory reactions in the gastrointestinal tract. IMM-124E was initially developed as an antidote for arsenic poisoning but also shows promising results in the treatment of inflammatory diseases such as nonalcoholic steatohepatitis (NASH) and liver fibrosis. IMM-124E is currently in phase II studies for the treatment of these conditions. In the field of infectious diseases, Immunic Inc is developing various drugs that are effective against infections. This includes IMU-935, a selective HSV-1 inhibitor that has shown promise in the treatment of herpes simplex viruses (HSV) and other viral infections. IMU-935 also exhibits good activity against influenza viruses and cytomegaloviruses and is currently in phase I studies. Immunic Inc is an innovative biotechnology company developing innovative therapeutics for chronic inflammatory and autoimmune diseases. The company aims to improve the lives of patients with chronic conditions and positively influence the course of their diseases. By focusing on three different areas, the company is developing a broad portfolio of drugs in various stages of development and clinical testing. Immunic Inc has established strong partnerships with academic, regulatory, and pharmaceutical partners and will continue to operate successfully in the biotechnology field with promising products and pipelines in the coming years.

Immunic SWOT Analysis

Strengths

Immunic Inc possesses several strengths that contribute to its success and competitive advantage in the market. These strengths include:

  • Strong pipeline of innovative pharmaceutical products.
  • Robust research and development capabilities.
  • Experienced and talented team of professionals.
  • Strategic partnerships with industry leaders.
  • Strong financial position and access to funding.

Weaknesses

Despite its strengths, Immunic Inc also faces some weaknesses that may hinder its growth and performance. These weaknesses include:

  • Relatively small market presence compared to major competitors.
  • Limited marketing and distribution capabilities.
  • Dependence on a few key products for revenue generation.
  • Potential regulatory challenges and uncertainties.
  • Vulnerability to changes in healthcare policies and regulations.

Opportunities

Immunic Inc can capitalize on various opportunities to further enhance its market position and generate growth. These opportunities include:

  • Increasing demand for innovative treatments in the pharmaceutical industry.
  • Expanding market potential across different therapeutic areas.
  • Global expansion and entering new geographic markets.
  • Collaboration opportunities with academic institutions and research organizations.
  • Advancements in technology and digital health solutions.

Threats

Immunic Inc must also consider various threats that could impact its business and market position negatively. These threats include:

  • Intense competition from existing and emerging pharmaceutical companies.
  • Rapidly changing market dynamics and evolving customer preferences.
  • Potential intellectual property infringements and legal disputes.
  • Uncertainty surrounding healthcare reforms and pricing pressures.
  • Possibility of adverse side effects or safety concerns of its products.

Immunic Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Immunic historical P/E ratio, EBIT multiple, and P/S ratio

Immunic annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Immunic shares outstanding

The number of shares of Immunic was 15.57 M in 2025. This indicates how many shares Immunic is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
2.53 M Stocks
Jan 1, 2022
3.18 M Stocks
Jan 1, 2023
4.46 M Stocks
Jan 1, 2024
9.02 M Stocks
Jan 1, 2025
15.57 M Stocks
Jan 1, 2026 (e)
15.57 M Stocks
Jan 1, 2027 (e)
15.57 M Stocks
Jan 1, 2028 (e)
15.57 M Stocks

Immunic stock splits

In Immunic's history, there have been no stock splits.

Current Immunic forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy93.33 % (14)
Hold6.67 % (1)
Sell0.00 % (0)
12M Price Target
4.08
Last Price
14.69
Currency
USD
12M Return Potential
-72.23 %
LTM Return
0 %

Immunic Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
5/13/2026-0.93USD0.00USD2026 Q1
2/19/2026-0.09USD0.00USD2025 Q4
5/9/2024-0.49USD0.00USD2024 Q1
2/21/2024-0.51USD0.00USD2023 Q4
8/2/2023-0.54USD0.00USD2023 Q2
5/8/2023-0.53USD0.00USD2023 Q1
2/22/2023-0.76USD0.00USD2022 Q4
11/3/2022-0.67USD0.00USD2022 Q3
8/4/2022-0.73USD0.00USD2022 Q2
5/10/2022-0.82USD0.00USD2022 Q1

EESG©

Eulerpool ESG Scorecard© for the Immunic stock

42/100
41
Environment
74
Social
11
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Immunic shareholder structure

% Name
6.85396%
abrdn Inc.
abrdn Inc.
6.36263%
BVF Partners L.P.
BVF Partners L.P.
6.06336%
Soleus Capital Management, L.P.
Soleus Capital Management, L.P.
4.66895%
Avidity Partners Management LP
Avidity Partners Management LP
3.42962%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
2.99595%
Morgan Stanley & Co. LLC
Morgan Stanley & Co. LLC
...

Immunic Executives and Management Board

DV

Dr. Daniel Vitt

(56)

Chief Executive Officer, Director · since 2019

Compensation2.94 M USD
AM

Dr. Andreas Muehler

(61)

Chief Medical Officer

Compensation1.37 M USD
DN

Dr. Duane Nash

(54)

Executive Chairman of the Board · since 2012

Compensation1.21 M USD
GW

Mr. Glenn Whaley

(57)

Chief Financial Officer

Compensation1.17 M USD
JT

Mr. Jason Tardio

(48)

President, Chief Operating Officer

Compensation1.03 M USD

Frequently asked questions about Immunic

Immunic Inc is primarily present in the United States.

All fundamentals and in-depth analysis of Immunic

Our stock analysis for Immunic stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunic. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Immunic Stock
Immunic Revenue→
Immunic Stock
Immunic Net Income→
Immunic Stock
Immunic P/E→
Immunic Stock
Immunic P/S→
Immunic Stock
Immunic EBIT→
Immunic Stock
Immunic Dividend→
Immunic Stock
Immunic Directors Dealings→
Immunic Stock
Immunic Stocks→
Immunic Stock
Immunic Market capitalization→
Immunic Stock
Immunic Debt→
Immunic Stock
Immunic Liabilities→
Immunic Stock
Immunic Equity→
Immunic Stock
Immunic AAQS→
Immunic Stock
Immunic Employees→
Immunic Stock
Immunic ROE→
Immunic Stock
Immunic ROA→
Immunic Stock
Immunic ROCE→
Immunic Stock
Immunic News→
Immunic Stock
Immunic Analyst Price Targets→

Health Stocks

ImmunitybioImmuneOnco Biopharmaceuticals ShanghaiImmuno-Biological Laboratories CoImmuneOncia TherapeuticsImmunocore HoldingsImmuneeringImmunomeImmuCellImmunotech BiopharmImmix BiopharmaImmunotech LaboratoriesImmaticsAll Stocks A–Z →